A question often asked by health-care providers is whether metformin has added benefits if continued after patients with type 2 diabetes mellitus switch to insulin. Beneficial effects on macrovascular end points observed in response to sustained metformin therapy argue in favor of this approach, according to new research from The Netherlands.
References
Nathan, D. M. et al. Medical management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193–203 (2009).
Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545–2559 (2008).
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).
Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139 (2009).
Kooy, A. et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169, 616–625 (2009).
Wulffelé, M. G. et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25, 2133–2140 (2002).
[No authors listed]. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).
Evans, R. M., Barish, G. D. & Wang, Y. U. PPARs and the complex journey to obesity. Nat. Med. 10, 355–361 (2004).
Wang, Y., Beydoun, M. A., Liang, L., Caballero, B. & Kumanyika, S. K. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) 16, 2323–2330 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares associations with the following companies: Amylin (consultant; grant/research support), Eli Lilly (consultant; grant/research support), Halozyme (consultant), Johnson & Johnson (consultant; grant/research support), and Merck (consultant; grant/research support).
Rights and permissions
About this article
Cite this article
Cefalu, W. HOME reveals new data on a cornerstone of treatment. Nat Rev Endocrinol 5, 478–479 (2009). https://doi.org/10.1038/nrendo.2009.154
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.154
- Springer Nature Limited